Shrestha Manash, Acharya Sanjaya, Neukom Josselyn, Lhazeen Karma, Thang Ngo Duc, Habib Muhammad Naeem, Wini Lyndes, Tobgyel Tobgyel, Wangchuk Kesang, Rekol Huy, Dysoley Lek, Sovannaroth Siv, Simatuopang Minerva, Prameswari Helen Dewi, Surya Asik, Ring Zau, Khan Mohammad Qasim, Khamlome Boualam, Hamid Mohd Hafizi Abdul, Mahato Ram Kumar, Thapa Top, Juangco Sheen Angelou, Lee Hee Il, Shin Hyun Il, Gunasekera Kumudu, Aluthwera Champa, Sudathip Prayuth, Timpontree Rungrawee, Canh Hoang Dinh, Cheung Sonia, Haroon Muhammad Zeeshan, Acharya Shreehari, Commons Robert J, Adhikari Bipin, Ruwanpura Varunika, Hein Phone Si, Sharma Abhijit, Aung Poe Poe, Valecha Neena, Thriemer Kamala, Lynch Caroline A
Asia Pacific Malaria Elimination Network (APMEN), Singapore, Singapore.
Medicines for Malaria Venture (MMV), Geneva, Switzerland.
Malar J. 2025 Jun 12;24(1):187. doi: 10.1186/s12936-025-05432-4.
Plasmodium vivax malaria remains a major challenge in the Asia-Pacific region, where National Malaria Programmes (NMPs) will need to determine optimal radical cure strategies given the availability of novel options, such as high-dose primaquine and tafenoquine. The Options Assessment Toolkit (OAT) was developed to assist NMPs to make decisions on the optimal combination of G6PD testing and radical cure drug regimen. This study reports on the piloting of OAT with NMP representatives during the APMEN Vivax Working Group Annual Meeting in December 2022. A total of 23 NMP representatives from 13 Asia-Pacific countries participated in facilitated discussions. Thematic analysis of qualitative data revealed that NMPs found the OAT useful and timely for structuring malaria policy discussions. However, concerns were raised regarding mismatches between OAT-generated scenarios and country-specific contexts, the inclusion of political and economic factors, and the feasibility of implementing expert-suggested options. Many NMPs expressed enthusiasm for single-dose tafenoquine, but preferred to await WHO recommendations before considering policy changes. Overall, the OAT was well received as a tool for initiating policy discussions on P. vivax radical cure. The OAT represents an important step toward accelerating evidence-based policy change in malaria-endemic countries, with further refinements enhancing its utility.
间日疟原虫疟疾仍是亚太地区面临的一项重大挑战，鉴于高剂量伯氨喹和tafenoquine等新选择的出现，各国国家疟疾防治计划（NMPs）需要确定最佳的根治策略。开发了选项评估工具包（OAT），以协助各国国家疟疾防治计划就葡萄糖-6-磷酸脱氢酶（G6PD）检测和根治药物方案的最佳组合做出决策。本研究报告了在2022年12月亚太疟疾和消除疟疾网络间日疟工作组年度会议期间与各国国家疟疾防治计划代表对选项评估工具包进行的试点情况。来自13个亚太国家的总共23名国家疟疾防治计划代表参加了促进性讨论。对定性数据的主题分析表明，各国国家疟疾防治计划认为选项评估工具包对构建疟疾政策讨论很有用且及时。然而，有人对选项评估工具包生成的情景与各国具体情况之间的不匹配、政治和经济因素的纳入以及实施专家建议选项的可行性表示担忧。许多国家疟疾防治计划对单剂量tafenoquine表示出热情，但更愿意等待世界卫生组织的建议后再考虑政策变化。总体而言，选项评估工具包作为启动关于间日疟原虫根治政策讨论的工具受到了好评。选项评估工具包是疟疾流行国家加速基于证据的政策变革的重要一步，进一步完善将提高其效用。
